MedTrace Logo

Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis

NCT04528277 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1050

Last updated 2020-08-27

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of the 1-month regimen of three times weekly rifapentine plus isoniazid in improving fertility outcome in recurrent implantation failure (RIF) patients with latent genital tuberculosis (LGTB), compared to no treatment and non-LGTB patients.

Conditions

  • Infertility, Female
  • Recurrent Implantation Failure
  • Genital Tuberculoses, Female
  • Genital Tuberculosis, Latent

Interventions

DRUG

rifapentine plus isoniazid

receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)

Sponsors & Collaborators

  • Shanghai First Maternity and Infant Hospital

    collaborator OTHER

  • Huashan Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-09-01
Completion
2022-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04528277 on ClinicalTrials.gov